Market closedNon-fractional
Ultragenyx Pharmaceutical/RARE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Ultragenyx Pharmaceutical
Ticker
RARE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Novato, United States
Employees
1,276
Website
www.ultragenyx.com
RARE Metrics
BasicAdvanced
$4.1B
Market cap
-
P/E ratio
-$7.96
EPS
0.60
Beta
-
Dividend rate
Price and volume
Market cap
$4.1B
Beta
0.6
Financial strength
Current ratio
2.427
Quick ratio
2.087
Long term debt to equity
625.038
Total debt to equity
664.585
Interest coverage (TTM)
-8.77%
Management effectiveness
Return on assets (TTM)
-26.97%
Return on equity (TTM)
-340.05%
Valuation
Price to revenue (TTM)
7.842
Price to book
26.53
Price to tangible book (TTM)
-53.78
Price to free cash flow (TTM)
-6.384
Growth
Revenue change (TTM)
15.29%
Earnings per share change (TTM)
-22.34%
3-year revenue growth (CAGR)
9.82%
3-year earnings per share growth (CAGR)
35.14%
What the Analysts think about RARE
Analyst Ratings
Majority rating from 21 analysts.
RARE Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$109M
-14.53%
Net income
-$171M
38.59%
Profit margin
-156.80%
62.15%
RARE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.25
-$2.23
-$1.52
-$2.03
-
Expected
-$2.07
-$2.08
-$1.62
-$1.73
-$1.71
Surprise
8.47%
7.31%
-6.15%
17.24%
-
RARE News
AllArticlesVideos
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Benzinga·4 days ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical (RARE) has a market cap of $4.1B as of July 27, 2024.
What is the P/E ratio for Ultragenyx Pharmaceutical stock?
The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of July 27, 2024.
Does Ultragenyx Pharmaceutical stock pay dividends?
No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Ultragenyx Pharmaceutical dividend payment date?
Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.
What is the beta indicator for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Ultragenyx Pharmaceutical stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.